Manifaxine
Manifaxine (GW-320,659) is a drug developed by GlaxoSmithKline through structural modification of radafaxine, one of the major active metabolites of bupropion. It acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). It was researched for treatment of ADHD and obesity and was shown to be safe, reasonably effective and well tolerated for both applications, but no results have been reported following these initial trials and its current status is unclear.
Wikipage redirect
primaryTopic
Manifaxine
Manifaxine (GW-320,659) is a drug developed by GlaxoSmithKline through structural modification of radafaxine, one of the major active metabolites of bupropion. It acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). It was researched for treatment of ADHD and obesity and was shown to be safe, reasonably effective and well tolerated for both applications, but no results have been reported following these initial trials and its current status is unclear.
has abstract
Manifaxine (GW-320,659) is a d ...... its current status is unclear.
@en
マニファキシン(Manifaxine)は、グラクソ・スミスク ...... 初の治験の後は結果の報告がなく、現在の状況は明らかではない。
@ja
ATC prefix
CAS number
135306-39-7
FDA UNII code
J8IE53G2IV
IUPAC name
(2S,3S,5R)-2-(3,5-difluorophenyl)-3,5-dimethylmorpholin-2-ol
@en
PubChem
thumbnail
Wikipage page ID
20,268,049
Wikipage revision ID
713,216,018
ChemSpiderID
molecular weight
2.43249e+2
smiles
C[C@@H]1CO[C@]O
StdInChIKey
OZGPVYJHWWPEFT-RGNHYFCHSA-N
Verifiedfields
verifiedrevid
449,582,256
Watchedfields
subject
comment
Manifaxine (GW-320,659) is a d ...... its current status is unclear.
@en
マニファキシン(Manifaxine)は、グラクソ・スミスク ...... 初の治験の後は結果の報告がなく、現在の状況は明らかではない。
@ja
label
Manifaxine
@en
マニファキシン
@ja